Home » Topics » Endocrine/metabolic, BioWorld Science

Endocrine/metabolic, BioWorld Science
RSS

Orquest's Healos enters clinical trials

June 21, 1996

Calcium receptor modulators from NPS Pharm.

June 21, 1996

Vivus and Astra sign Muse licensing agreement

June 14, 1996

Further aldose reductase inhibitors from Sankyo

June 14, 1996

Aldose reductase and AGE inhibitors from Nissan Chem.

June 14, 1996

Troglitazone selected for NIDDK study

June 14, 1996

Antidiabetic agents reported by Boehringer Mannheim

June 14, 1996

rHb1.1 phase I trials begin in end-stage renal disease

June 14, 1996

SC-55494 effective in combination with rhG-CSF

June 14, 1996

CCK-A agonists revealed by Glaxo Wellcome

June 14, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 1, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
BMS’ mezigdomide doubles PFS in multiple myeloma
BioWorld
Bristol Myers Squibb Co. disclosed in March 2026 that the phase III portion of the seamless phase II/III Successor-2 study testing mezigdomide in combination with...
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
ADCs, multispecific antibodies anchor $10B Pfizer-Innovent deal
BioWorld
Pfizer Inc. is paying Innovent Biologics Co. Ltd. $650 million up front and up to $9.85 billion in milestones, plus royalties, to collaborate across 12 early...